Vol 9 (June 30, 2026): Gynecology and Pelvic Medicine

Editorial Commentary
Treatment of recurrent low grade serous ovarian cancer: MEK inhibition and the RAMP 201 trial
Maryam Ali, Rebecca Brooks
Gynecology and Pelvic Medicine  
2026;
9:
22
.
Editorial Commentary
Evaluation of results from KEYNOTE-826 and its impact within the East Asian population with real-world applications
Christopher M. Mayer, Charles A. Leath III
Gynecology and Pelvic Medicine  
2026;
9:
21
.
Editorial Commentary
Efficacy at a cost: camrelizumab and famitinib within the expanding landscape of combination therapies
Teresa Zumarraga-Lizundia, Arantzazu Barquin-Garcia, Ainhoa Madariaga
Gynecology and Pelvic Medicine  
2026;
9:
20
.
Review Article
Is occult stress urinary incontinence truly “occult”?
Xingqi Wang, Ling Li, Zhenhua Gao, Daoming Tian, Yuan Li, Jiangna Gu, Hongcheng Li, Qian Luo, Jihong Shen
Gynecology and Pelvic Medicine  
2026;
9:
14
.
Original Article
Uterine fibroids reduce the sensitivity of ultrasound to detect endometrioid and serous endometrial cancer: a retrospective cohort study
Anna J. Najor, Tori B. Aspir, Alexander J. Fife, Udele J. Tagoe, Nada M. Hussein, Sheila T. Moran, Kelsea R. Grant, Sara S. Isani, Matthew W. Cowan, Nicole S. Nevadunsky, Ohad D. Rotenberg, Ken Y. Lin
Gynecology and Pelvic Medicine  
2026;
9:
13
.
Original Article
Mapping the knowledge landscape of lymph node metastasis in ovarian cancer: a bibliometric and collaboration network analysis
Chunru Chen, Xiaohua Cheng, Yingjie Zhang, Chenyang Cui, Yanan Peng, Juan Wang, Wenting Li, Fuxia Li
Gynecology and Pelvic Medicine  
2026;
9:
11
.